BI 653048

Drug Profile

BI 653048

Alternative Names: BI 653048 BS H3PO4; BI 653048 H3PO4

Latest Information Update: 10 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antirheumatics; Benzamides; Indoles; Pyridines; Pyrroles
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 31 Dec 2013 Phase-I development is ongoing in Germany
  • 31 Mar 2010 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT02217631)
  • 31 Oct 2009 Boehringer Ingelheim initiates enrolment in a phase I trial in Healthy volunteers in Germany (NCT02217631)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top